A_DT randomised_VBN controlled_JJ trial_NN of_IN a_DT patient_NN based_VBN Diabetes_NP recall_NN and_CC Management_NN system_NN :_: the_DT DREAM_NP trial_NN :_: A_DT study_NN protocol_NN [_SYM ISRCTN32042030_NP ]_SYM Abstract_NP |_SYM Background_NN |_SYM Whilst_IN there_EX is_VBZ broad_JJ agreement_NN on_IN what_WP constitutes_VBZ high_JJ quality_NN health_NN care_NN for_IN people_NNS with_IN diabetes_NN ,_, there_EX is_VBZ little_JJ consensus_NN on_IN the_DT most_RBS efficient_JJ way_NN of_IN delivering_VBG it_PP ._SENT Structured_JJ recall_NN systems_NNS can_MD improve_VB the_DT quality_NN of_IN care_NN but_CC the_DT systems_NNS evaluated_VBN to_TO date_NN have_VBP been_VBN of_IN limited_JJ sophistication_NN and_CC the_DT evaluations_NNS have_VBP been_VBN carried_VBN out_RP in_IN small_JJ numbers_NNS of_IN relatively_RB unrepresentative_JJ settings_NNS ._SENT Hartlepool_NP ,_, Easington_NP and_CC Stockton_NP currently_RB operate_VBP a_DT computerised_VBN diabetes_NN register_NN which_WDT has_VBZ to_TO date_VB produced_VBN improvements_NNS in_IN the_DT quality_NN of_IN care_NN but_CC performance_NN has_VBZ now_RB plateaued_VBN leaving_VBG substantial_JJ scope_NN for_IN further_JJR improvement_NN ._SENT This_DT study_NN will_MD evaluate_VB the_DT effectiveness_NN and_CC efficiency_NN of_IN an_DT area_NN wide_RB '_'' extended_VBN '_'' system_NN incorporating_VBG a_DT full_JJ structured_JJ recall_NN and_CC management_NN system_NN ,_, actively_RB involving_VBG patients_NNS and_CC including_VBG clinical_JJ management_NN prompts_VBZ to_TO primary_JJ care_NN clinicians_NNS based_VBN on_IN locally-adapted_JJ evidence_NN based_VBN guidelines_NNS ._SENT Methods_NNS |_SYM The_DT study_NN design_NN is_VBZ a_DT two-armed_JJ cluster_NN randomised_VBD controlled_JJ trial_NN of_IN 61_CD practices_NNS incorporating_VBG evaluations_NNS of_IN the_DT effectiveness_NN of_IN the_DT system_NN ,_, its_PP$ economic_JJ impact_NN and_CC its_PP$ impact_NN on_IN patient_JJ wellbeing_NN and_CC functioning_NN ._SENT Delivering_VBG care_NN to_TO people_NNS with_IN diabetes_NN |_SYM There_EX is_VBZ broad_JJ ,_, international_JJ agreement_NN over_IN what_WP constitutes_VBZ high_JJ quality_NN health_NN care_NN for_IN people_NNS with_IN diabetes_NN ._SENT This_DT will_MD be_VB enshrined_VBN in_IN a_DT National_NP Service_NP Framework_NP for_IN people_NNS with_IN diabetes_NN ,_, due_JJ in_IN summer_NN 2002_CD ._SENT However_RB ,_, in_IN the_DT face_NN of_IN poor_JJ current_JJ performance_NN the_DT most_RBS efficient_JJ method_NN of_IN delivering_VBG care_NN remains_VBZ unclear_JJ ._SENT Following_VBG a_DT 1994_CD systematic_JJ literature_NN review_NN suggesting_VBG structured_JJ care_NN improved_VBD patient_JJ care_NN ,_, an_DT editorial_NN in_IN the_DT British_NP Medical_NP Journal_NP concluded_VBD that_IN more_RBR evaluative_JJ research_NN was_VBD needed_VBN before_IN widespread_JJ adoption_NN of_IN any_DT of_IN the_DT models_NNS could_MD be_VB recommended_VBN ._SENT A_DT subsequent_JJ systematic_JJ review_NN of_IN routine_JJ surveillance_NN of_IN patients_NNS with_IN diabetes_NN by_IN Griffin_NP and_CC Kinmonth_NP concluded_VBD "_`` Computerised_JJ central_JJ recall_NN ,_, with_IN prompting_VBG for_IN patients_NNS and_CC their_PP$ family_NN doctors_NNS ,_, can_MD achieve_VB standards_NNS of_IN care_NN as_IN good_JJ or_CC better_RBR than_IN hospital_NN outpatient_NN care_NN ,_, at_IN least_JJS in_IN the_DT short_JJ term_NN ._SENT The_DT evidence_NN supports_VBZ provision_NN of_IN regular_JJ prompted_VBN recall_NN and_CC review_NN of_IN people_NNS with_IN diabetes_NN by_IN willing_JJ general_JJ practitioners_NNS and_CC demonstrates_VBZ that_IN this_DT can_MD be_VB achieved_VBN ,_, if_IN suitable_JJ organisation_NN is_VBZ in_IN place_NN '_POS ._SENT However_RB ,_, the_DT evidence_NN base_NN on_IN which_WDT these_DT conclusions_NNS are_VBP based_VBN is_VBZ limited_VBN in_IN several_JJ ways_NNS ._SENT Firstly_RB there_EX are_VBP only_RB five_CD randomised_VBD controlled_JJ trials_NNS (_( RCTs_NP )_) involving_VBG 1058_CD patients_NNS ._SENT All_DT of_IN these_DT studies_NNS are_VBP '_POS patient_NN randomised_VBD "_`` trials_NNS ,_, thus_RB potentially_RB under-estimating_VBG the_DT effectiveness_NN of_IN the_DT intervention_NN (_( see_VB Study_NP Design_NP )_) ._SENT They_PP were_VBD all_RB evaluating_VBG more_JJR or_CC less_JJR selected_JJ patients_NNS and_CC general_JJ practices_NNS and_CC none_NN of_IN them_PP were_VBD explicitly_RB evaluating_VBG a_DT UK_NP National_NP Health_NP Service_NP (_( NHS_NN )_) service_NN area_NN wide_JJ intervention_NN ._SENT Only_RB one_CD of_IN the_DT four_CD UK_NP based_VBN studies_NNS evaluated_VBD patient_JJ based_VBN outcomes_NNS and_CC included_VBD an_DT economic_JJ assessment_NN and_CC this_DT study_NN only_RB involved_VBN patients_NNS from_IN three_CD general_JJ practices_NNS ._SENT Thus_RB ,_, the_DT effectiveness_NN of_IN an_DT area_NN wide_JJ ,_, patient_JJ focussed_VBD ,_, structured_JJ recall_NN and_CC management_NN system_NN (_( in_IN terms_NNS of_IN process_NN of_IN care_NN ,_, patient_JJ outcome_NN and_CC economic_JJ impact_NN )_) remains_VBZ unknown_JJ ._SENT The_DT current_JJ system_NN |_SYM The_DT current_JJ computerised_VBN diabetes_NN management_NN system_NN runs_VBZ in_IN Hartlepool_NP ,_, Easington_NP and_CC Stockton_NP ,_, three_CD Primary_NP Care_NP Group_NP (_( PCG_NP )_) areas_NNS ,_, in_IN the_DT Northern_NP and_CC Yorkshire_NP Region_NP ._SENT It_PP was_VBD introduced_VBN to_TO all_DT 36_CD general_JJ practices_NNS in_IN Hartlepool_NP and_CC Easington_NP Districts_NP in_IN mid-1995_NP ._SENT Stockton_NP (_( 25_CD practices_NNS )_) agreed_VBD to_TO join_VB the_DT system_NN in_IN 1999_CD and_CC it_PP was_VBD operational_JJ there_RB by_IN October_NP 2000_CD ._SENT There_EX are_VBP three_CD key_JJ components_NNS to_TO the_DT current_JJ system_NN :_: 1_LS ._SENT A_DT central_JJ register_NN of_IN patients_NNS with_IN diabetes_NN ._SENT 2_LS ._SENT A_DT structured_JJ minimum_JJ dataset_NN to_TO be_VB completed_VBN and_CC returned_VBN to_TO the_DT central_JJ register_NN ._SENT 3_LS ._SENT The_DT provision_NN of_IN both_DT patient_JJ specific_JJ and_CC aggregated_VBN data_NNS to_TO both_DT patients_NNS and_CC clinicians_NNS ._SENT The_DT system_NN (_( developed_VBN by_IN Westman_NP Medical_NP Software_NP )_) allows_VBZ three_CD methods_NNS of_IN collection_NN of_IN data_NNS at_IN each_DT contact_NN with_IN a_DT patient_NN with_IN diabetes_NN who_WP is_VBZ registered_VBN on_IN the_DT database_NN ._SENT Two_CD methods_NNS use_VBP a_DT standard_JJ form_NN completed_VBN by_IN clinicians_NNS to_TO collect_VB data_NNS concordant_JJ with_IN the_DT UK_NP minimum_NN data_NNS set_VBD ._SENT Within_IN secondary_JJ care_NN ,_, forms_NNS are_VBP completed_VBN at_IN every_DT new_JJ patient_NN or_CC annual_JJ review_NN ._SENT In_IN primary_JJ care_NN ,_, forms_NNS are_VBP completed_VBN by_IN the_DT practice_NN nurse_NN (_( usually_RB )_) or_CC general_JJ practitioner_NN ,_, either_CC opportunistically_RB or_CC at_IN practice_NN diabetic_NN clinics_NNS ._SENT In_IN both_DT cases_NNS ,_, the_DT completed_VBN data_NN forms_NNS are_VBP sent_VBN to_TO the_DT Diabetes_NP Register_NP Facilitator_NP for_IN data_NN entry_NN ._SENT Thirdly_RB ,_, the_DT hospital_NN laboratory_NN provides_VBZ a_DT monthly_JJ download_NN of_IN laboratory_NN test_NN details_NNS (_( e.g._FW HbA1c_NP )_) ._SENT A_DT patient_NN can_MD be_VB identified_VBN as_IN having_VBG diabetes_NN and_CC added_VBD to_TO the_DT register_NN by_IN any_DT permutation_NN of_IN one_CD or_CC more_JJR of_IN these_DT three_CD routes_NNS ._SENT Feedback_NN of_IN individual_JJ patients_NNS '_POS data_NNS ,_, including_VBG review_NN status_NN ,_, is_VBZ provided_VBN to_TO general_JJ practices_NNS quarterly_JJ ._SENT This_DT feedback_NN is_VBZ '_'' passive_NN '_'' in_IN that_WDT it_PP does_VBZ not_RB explicitly_RB prompt_VB either_DT patients_NNS or_CC doctors_NNS as_RB to_TO required_VBN actions_NNS ._SENT Audit_NN packages_NNS within_IN the_DT software_NN can_MD audit_VB on_IN every_DT variable_NN collected_VBD ._SENT District_NP wide_JJ audit_NN is_VBZ provided_VBN on_IN anonymised_JJ aggregated_VBN data_NNS ;_: individual_JJ practice_NN audits_NN (_( with_IN comparisons_NNS to_TO other_JJ practices_NNS )_) are_VBP provided_VBN to_TO participating_VBG practices_NNS at_IN least_JJS annually_RB ._SENT Feedback_NN of_IN the_DT data_NNS to_TO the_DT patient_NN (_( for_IN hospital_NN patients_NNS only_RB )_) is_VBZ by_IN a_DT patient_JJ information_NN sheet_NN and_CC to_TO the_DT GP_NN as_IN a_DT standardised_VBN letter_NN ._SENT A_DT Diabetes_NP Register_NP Facilitator_NP co-ordinates_VBZ and_CC updates_VBZ the_DT register_NN ._SENT A_DT steering_NN group_NN composed_VBN of_IN GH_NP ,_, the_DT Diabetes_NP Register_NP Facilitator_NP and_CC representatives_NNS of_IN the_DT PCGs_NNS and_CC patients_NNS ,_, oversees_VBZ the_DT register_NN and_CC deals_NNS with_IN issues_NNS such_JJ as_IN confidentiality_NN ._SENT Impact_NN of_IN the_DT system_NN to_TO date_NN |_SYM Measures_NNS of_IN the_DT impact_NN of_IN the_DT system_NN to_TO date_VB relate_VB only_RB to_TO Hartlepool_NP ,_, Easington_NP and_CC Stockton_NP ._SENT The_DT main_JJ impact_NN on_IN patient_JJ registration_NN was_VBD in_IN its_PP$ first_JJ 12_CD to_TO 18_CD months_NNS of_IN operation_NN :_: during_IN 1995_CD ,_, 747_CD patients_NNS were_VBD registered_VBN on_IN the_DT system_NN (_( 0.4_CD %_NN prevalence_NN )_) which_WDT had_VBD increased_VBN to_TO 3867_CD (_( 1.8_CD %_NN prevalence_NN )_) by_IN the_DT end_NN of_IN 1996_CD ._SENT The_DT increase_NN in_IN registration_NN has_VBZ stabilised_VBN since_IN then_RB ,_, reaching_VBG 4324_CD (_( 2_CD %_NN prevalence_NN )_) by_IN 1999_CD ._SENT During_IN 1999_CD ,_, 70_CD %_NN of_IN registered_JJ patients_NNS attended_VBD a_DT clinic_NN ;_: 52_CD %_NN had_VBD their_PP$ feet_NNS examined_VBD and_CC 51_CD %_NN had_VBD their_PP$ eyes_NNS examined_VBD ._SENT Seventy_CD three_CD per_IN cent_NN had_VBD an_DT HbA1c_NP result_NN recorded_VBD and_CC 69_CD %_NN a_DT blood_NN pressure_NN measurement_NN ._SENT These_DT figures_NNS are_VBP similar_JJ to_TO those_DT reported_VBN by_IN other_JJ centres_NNS using_VBG the_DT same_JJ system_NN ._SENT The_DT need_NN for_IN an_DT extended_JJ system_NN |_SYM Recording_NP of_IN clinical_JJ measures_NNS increased_VBN during_IN the_DT first_JJ few_JJ years_NNS of_IN operation_NN of_IN the_DT system_NN but_CC began_VBD to_TO plateau_NN more_JJR recently_RB (_( for_IN example_NN ,_, 50_CD %_NN of_IN patients_NNS had_VBD an_DT HbA1c_NP recorded_VBD during_IN 1996_CD ,_, compared_VBN to_TO 60_CD %_NN in_IN 1997_CD and_CC 63_CD %_NN in_IN 1998_CD )_) ._SENT This_DT plateauing_VBG of_IN performance_NN has_VBZ been_VBN reported_VBN by_IN others_NNS ._SENT We_PP believe_VBP that_IN this_DT is_VBZ due_JJ to_TO a_DT lack_NN of_IN coordination_NN (_( patients_NNS being_VBG lost_VBN to_TO follow_VB up_RP )_) and_CC lack_NN of_IN prompting_VBG of_IN clinicians_NNS to_TO deliver_VB appropriate_JJ clinical_JJ interventions_NNS ._SENT Furthermore_RB ,_, given_VBN that_IN most_JJS patients_NNS with_IN diabetes_NN are_VBP primarily_RB seen_VBN in_IN primary_JJ care_NN the_DT greatest_JJS potential_JJ impact_NN is_VBZ from_IN optimising_VBG and_CC extending_VBG the_DT system_NN in_IN primary_JJ care_NN ._SENT In_IN order_NN to_TO address_VB these_DT shortcomings_NNS the_DT additional_JJ key_JJ components_NNS ,_, over_IN and_CC above_IN those_DT already_RB in_IN the_DT system_NN ,_, will_MD be_VB :_: 1_LS ._SENT Locally_RB adapted_VBN evidence_NN based_VBN guidelines_NNS for_IN the_DT management_NN and_CC follow_VB up_RP of_IN patients_NNS with_IN diabetes_NN ._SENT 2_LS ._SENT Automated_JJ prompts_NNS to_TO patients_NNS and_CC primary_JJ care_NN clinicians_NNS that_IN a_DT review_NN consultation_NN is_VBZ necessary_JJ ._SENT 3_LS ._SENT A_DT structured_JJ management_NN sheet_NN (_( including_VBG patient_JJ specific_JJ management_NN suggestions_NNS based_VBN on_IN (_( 1_LS )_) )_) ._SENT 4_LS ._SENT An_DT enhanced_JJ monitoring_NN system_NN to_TO follow_VB up_RP reasons_NNS for_IN non-attendance_NN from_IN both_DT patients_NNS and_CC clinicians_NNS and_CC to_TO re-schedule_NN appointments_NNS ,_, based_VBN on_IN nonreturn_NN of_IN a_DT completed_VBN management_NN sheet_NN ._SENT 5_LS ._SENT Patient_JJ feedback_NN for_IN patients_NNS in_IN primary_JJ care_NN ._SENT There_EX is_VBZ some_DT limited_JJ supportive_JJ trial_NN evidence_NN for_IN these_DT developments_NNS ,_, although_IN the_DT existing_JJ studies_NNS involved_VBD small_JJ sample_NN sizes_NNS and_CC may_MD not_RB be_VB generalisable_JJ to_TO the_DT NHS_NN ._SENT In_IN evaluating_VBG the_DT system_NN with_IN these_DT extended_JJ features_NNS this_DT study_NN will_MD also_RB address_VB the_DT design_NN shortcomings_NNS of_IN previous_JJ studies_NNS of_IN shared_JJ care_NN in_IN diabetes_NN ._SENT It_PP will_MD be_VB tailored_VBN to_TO each_DT practice_NN ,_, PCG_NP defined_VBD areas_NNS will_MD be_VB studied_VBN ,_, rather_RB than_IN an_DT unrepresentative_JJ sample_NN of_IN general_JJ practices_NNS ;_: and_CC the_DT system_NN will_MD be_VB transparent_JJ and_CC replicable_JJ in_IN other_JJ areas_NNS ._SENT Design_NN of_IN the_DT study_NN |_SYM The_DT study_NN design_NN is_VBZ a_DT pragmatic_JJ two-arm_NN cluster_NN randomised_VBD controlled_JJ trial_NN ._SENT The_DT unit_NN of_IN randomisation_NN will_MD be_VB the_DT general_JJ practice_NN ._SENT Simple_JJ patient_NN randomised_VBD trials_NNS are_VBP rightly_RB considered_VBN the_DT most_RBS robust_JJ method_NN of_IN assessing_VBG most_JJS health_NN care_NN innovations_NNS ._SENT This_DT design_NN ,_, however_RB ,_, cannot_MD be_VB regarded_VBN as_IN the_DT gold_JJ standard_NN for_IN evaluating_VBG systematic_JJ approaches_NNS to_TO chronic_JJ disease_NN management_NN ,_, an_DT essentially_RB behavioural_JJ field_NN of_IN research_NN ._SENT If_IN both_DT intervention_NN and_CC control_NN patients_NNS were_VBD to_TO be_VB cared_VBN for_IN within_IN the_DT same_JJ practice_NN there_EX is_VBZ the_DT risk_NN that_IN the_DT management_NN of_IN control_NN patients_NNS would_MD be_VB influenced_VBN by_IN the_DT practitioners_NNS knowledge_NN of_IN the_DT care_NN of_IN intervention_NN patients_NNS ._SENT This_DT would_MD result_VB in_IN an_DT underestimation_NN of_IN the_DT effect_NN of_IN the_DT intervention_NN ._SENT Therefore_RB ,_, practices_NNS rather_RB than_IN patients_NNS are_VBP the_DT appropriate_JJ unit_NN of_IN randomisation_NN and_CC analysis_NN ._SENT As_IN the_DT current_JJ system_NN has_VBZ been_VBN in_IN place_NN for_IN different_JJ lengths_NNS of_IN time_NN within_IN the_DT three_CD participating_VBG PCGs_NNS ,_, we_PP will_MD stratify_VB the_DT randomisation_NN by_IN PCG_NP ._SENT Randomisation_NN will_MD be_VB performed_VBN by_IN a_DT statistician_NN independent_JJ of_IN the_DT research_NN team_NN using_VBG computer_NN generated_VBD numbers_NNS to_TO avoid_VB allocation_NN bias_NN ._SENT Study_NN setting_NN and_CC recruitment_NN of_IN practices_NNS |_SYM The_DT study_NN will_MD be_VB based_VBN in_IN the_DT general_JJ practices_NNS of_IN the_DT three_CD PCGs_NNS of_IN Easington_NP ,_, Hartlepool_NP and_CC Stockton_NP ._SENT Since_IN the_DT recent_JJ merger_NN of_IN Hartlepool_NP and_CC North_NP Tees_NP Acute_NP Trusts_VBZ all_DT three_CD PCGs_NNS are_VBP now_RB exclusively_RB served_VBN by_IN one_CD secondary_JJ care_NN diabetes_NN service_NN (_( and_CC thus_RB the_DT one_CD diabetes_NN register_NN )_) ._SENT GH_NP is_VBZ the_DT lead_JJ clinician_NN for_IN diabetes_NN services_NNS in_IN the_DT new_JJ Trust_NP ._SENT The_DT 61_CD general_JJ practices_NNS in_IN the_DT three_CD PCGs_NNS constitute_VBP the_DT target_NN practices_NNS for_IN the_DT study_NN and_CC we_PP will_MD attempt_VB to_TO recruit_VB all_DT practices_NNS ._SENT The_DT PCG_NP diabetes_NN leads_NNS or_CC the_DT PCG_NP clinical_JJ governance_NN leads_VBZ in_IN all_DT three_CD PCGs_NNS have_VBP provided_VBN letters_NNS confirming_VBG their_PP$ support_NN for_IN the_DT project_NN ._SENT We_PP do_VBP not_RB envisage_VB major_JJ difficulties_NNS with_IN recruitment_NN ,_, given_VBN the_DT need_NN to_TO agree_VB local_JJ guidelines_NNS as_IN part_NN of_IN the_DT process_NN involved_VBN in_IN the_DT Trust_NP merger_NN ,_, the_DT likely_JJ requirements_NNS in_IN the_DT forthcoming_JJ National_NP Service_NP Framework_NP for_IN diabetes_NN ,_, and_CC the_DT 100_CD %_NN practice_NN coverage_NN with_IN the_DT current_JJ diabetes_NN system_NN ._SENT We_PP will_MD (_( through_IN the_DT PCGs_NNS )_) write_VBP to_TO all_DT practices_NNS ,_, giving_VBG information_NN about_IN the_DT project_NN to_TO the_DT senior_JJ partner_NN or_CC diabetes_NN lead_NN and_CC practice_NN manager_NN of_IN practices_NNS ._SENT Practices_NNS will_MD be_VB invited_VBN to_TO opt_VB out_RP if_IN they_PP do_VBP not_RB wish_VB to_TO be_VB included_VBN in_IN the_DT study_NN --_: this_DT is_VBZ an_DT approach_NN we_PP have_VBP used_VBN successfully_RB before_RB ._SENT The_DT PCG_NP diabetes_NN lead_NN ,_, clinical_JJ governance_NN lead_NN and_CC GH_NP will_MD be_VB co-signatories_JJ of_IN this_DT letter_NN ._SENT If_IN practices_NNS do_VBP decline_NN we_PP will_MD collect_VB data_NNS on_IN characteristics_NNS of_IN non-participating_VBG practices_NNS to_TO assess_VB the_DT impact_NN on_IN the_DT generalisability_NN of_IN the_DT trial_NN 's_POS findings_NNS ._SENT Finally_RB ,_, if_IN there_EX are_VBP significant_JJ problems_NNS with_IN recruitment_NN ,_, there_EX are_VBP other_JJ practices_NNS which_WDT could_MD be_VB approached_VBN in_IN a_DT nearby_JJ PCG_NP (_( South_NP Tyneside_NP )_) which_WDT uses_VBZ the_DT same_JJ software_NN for_IN its_PP$ diabetes_NN register_NN ._SENT Details_NNS of_IN the_DT intervention_NN |_SYM Local_JJ guidelines_NNS and_CC management_NN prompts_NNS |_SYM A_DT guideline_NN development_NN group_NN will_MD be_VB established_VBN to_TO develop_VB local_JJ guidelines_NNS for_IN the_DT management_NN of_IN diabetes_NN ,_, based_VBN upon_IN available_JJ evidence_NN based_VBN guidelines_NNS (_( Scottish_NP Intercollegiate_NP Guidelines_NPS Network_NP (_( SIGN_NP ,_, 1996_CD ,_, 1997a_NP ,_, 1997b_NP ,_, 1997c_NP )_) ,_, and_CC Effective_NP Care_NP Bulletins_NP ._SENT They_PP will_MD also_RB use_VB the_DT forthcoming_JJ national_JJ diabetes_NN guidelines_NNS as_IN these_DT become_VBN available_JJ ._SENT The_DT group_NN will_MD be_VB multidisciplinary_JJ and_CC contain_VB primary_JJ and_CC secondary_JJ care_NN doctors_NNS and_CC nurses_NNS ,_, patients_NNS and_CC the_DT Diabetes_NP Register_NP Facilitator_NP ._SENT The_DT group_NN will_MD define_VB review_NN periods_NNS for_IN specified_JJ patient_JJ groups_NNS (_( e.g._FW patients_NNS with_IN diabetes_NN satisfactorily_RB controlled_VBN on_IN diet_NN alone_RB should_MD be_VB reviewed_VBN every_DT 12_CD months_NNS )_) ,_, referral_NN criteria_NNS for_IN patients_NNS moving_VBG from_IN primary_JJ to_TO secondary_JJ care_NN and_CC back_JJ and_CC simple_JJ decision_NN rules_NNS for_IN the_DT management_NN prompts_VBZ ._SENT These_DT would_MD be_VB of_IN two_CD types_NNS ._SENT The_DT first_JJ would_MD prompt_VB for_IN actions_NNS to_TO be_VB performed_VBN and_CC only_RB require_VB their_PP$ performance_NN to_TO be_VB documented_VBN (_( e.g._FW asking_VBG for_IN a_DT foot_NN examination_NN to_TO be_VB performed_VBN in_IN a_DT patient_NN who_WP does_VBZ not_RB have_VB a_DT recorded_JJ foot_NN examination_NN )_) ._SENT The_DT second_NN would_MD be_VB more_RBR complex_JJ and_CC suggest_VBP alterations_NNS to_TO clinical_JJ management_NN on_IN the_DT basis_NN of_IN data_NNS in_IN the_DT database_NN (_( e.g._FW patients_NNS with_IN persistently_RB raised_VBN blood_NN pressure_NN should_MD have_VB their_PP$ anti-hypertensive_JJ medication_NN increased_VBN )_) ._SENT These_DT decision_NN rules_NNS will_MD be_VB integrated_VBN into_IN the_DT recall_NN and_CC management_NN system_NN ._SENT Running_VBG the_DT system_NN |_SYM The_DT proposed_VBN enhancements_NNS to_TO the_DT system_NN are_VBP designed_VBN to_TO require_VB the_DT primary_JJ care_NN team_NN to_TO perform_VB no_DT additional_JJ work_NN over_IN and_CC above_IN the_DT current_JJ configuration_NN ._SENT The_DT current_JJ database_NN has_VBZ a_DT patient_JJ identifier_NN ,_, a_DT minimum_JJ dataset_NN and_CC retrieval_NN systems_NNS to_TO support_VB the_DT structured_JJ recall_NN of_IN patients_NNS ._SENT Westman_NP Medical_NP Software_NP has_VBZ agreed_VBN to_TO amend_VB the_DT system_NN as_RB required_VBN ._SENT A_NP '_POS circle_NN of_IN information_NN exchange_NN '_'' will_MD be_VB established_VBN between_IN the_DT participating_VBG general_JJ practices_NNS and_CC the_DT database_NN ._SENT The_DT local_JJ guidelines_NNS will_MD be_VB used_VBN to_TO adapt_VB the_DT current_JJ centralised_VBN database_NN ,_, along_RB with_IN the_DT practices_NNS '_POS preferred_JJ method_NN of_IN following_VBG up_RP patients_NNS (_( for_IN example_NN ,_, within_IN consultations_NNS in_IN routine_JJ surgeries_NNS or_CC within_IN special_JJ clinics_NNS )_) ._SENT The_DT central_JJ database_NN system_NN will_MD identify_VB when_WRB patients_NNS are_VBP due_JJ for_IN review_NN (_( based_VBN upon_IN the_DT local_JJ guidelines_NNS )_) and_CC will_MD generate_VB a_DT letter_NN to_TO the_DT patient_NN asking_VBG them_PP to_TO make_VB an_DT appointment_NN for_IN a_DT review_NN consultation_NN ._SENT Patient_JJ information_NN or_CC educational_JJ materials_NNS could_MD be_VB included_VBN with_IN the_DT letter_NN ._SENT At_IN the_DT same_JJ time_NN ,_, the_DT central_JJ database_NN will_MD generate_VB a_DT letter_NN to_TO the_DT practice_NN stating_VBG that_IN the_DT patient_NN should_MD be_VB making_VBG a_DT review_NN appointment_NN in_IN the_DT near_JJ future_NN ._SENT The_DT letter_NN to_TO the_DT practice_NN will_MD include_VB a_DT management_NN sheet_NN (_( to_TO be_VB held_VBN in_IN the_DT patient_NN 's_POS record_NN )_) to_TO capture_VB an_DT agreed_VBN minimum_NN data_NNS set_VBN to_TO be_VB collected_VBN during_IN the_DT consultation_NN ._SENT This_DT management_NN sheet_NN will_MD also_RB contain_VB the_DT relevant_JJ prompts_NNS (_( as_RB described_VBN above_IN )_) ._SENT When_WRB the_DT patient_NN is_VBZ seen_VBN in_IN the_DT practice_NN ,_, the_DT primary_JJ care_NN professional_NN (_( currently_RB this_DT is_VBZ usually_RB done_VBN by_IN the_DT practice_NN nurse_NN )_) will_MD complete_VB the_DT management_NN sheet_NN and_CC return_VB a_DT copy_NN for_IN entry_NN onto_IN the_DT central_JJ register_NN within_IN a_DT designated_VBN period_NN of_IN time_NN ._SENT This_DT circle_NN of_IN information_NN is_VBZ broken_VBN if_IN the_DT patient_NN does_VBZ not_RB visit_VB the_DT general_JJ practice_NN as_IN planned_JJ or_CC the_DT general_JJ practice_NN does_VBZ not_RB return_VB the_DT management_NN sheet_NN to_TO the_DT central_JJ register_NN ._SENT If_IN this_DT happens_VBZ ,_, the_DT central_JJ register_NN would_MD alert_VB the_DT Diabetes_NP Register_NP Facilitator_NP who_WP will_MD ascertain_VB the_DT reason_NN for_IN failure_NN and_CC take_VB appropriate_JJ action_NN ,_, (_( e.g._FW send_VB a_DT reminder_NN to_TO the_DT patient_NN ,_, prompt_VB the_DT practice_NN to_TO return_VB the_DT management_NN sheet_NN )_) ._SENT A_DT range_NN of_IN educational_JJ activities_NNS will_MD be_VB provided_VBN for_IN intervention_NN practices_NNS ,_, as_IN part_NN of_IN the_DT usual_JJ local_JJ structures_NNS for_IN contact_NN with_IN practices_NNS ,_, with_IN some_DT additions_NNS ,_, These_DT will_MD include_VB :_: distribution_NN of_IN information_NN about_IN the_DT trial_NN in_IN local_JJ newsletters_NNS ;_: meetings_NNS with_IN practice_NN clinical_JJ governance_NN leads_NNS ;_: evening_NN meetings_NNS for_IN practice_NN nurses_NNS (_( with_IN small_JJ group_NN discussion_NN of_IN the_DT practical_JJ implications_NNS for_IN intervention_NN practices_NNS )_) ;_: and_CC a_DT telephone_NN meeting_NN with_IN the_DT practice_NN diabetes_NN lead_NN (_( usually_RB the_DT practice_NN nurse_NN )_) in_IN each_DT intervention_NN practice_NN ._SENT Practices_NNS in_IN the_DT control_NN arm_NN will_MD continue_VB to_TO receive_VB the_DT recall_NN system_NN as_IN currently_RB configured_VBN ._SENT Logistical_JJ considerations_NNS |_SYM From_IN the_DT prevalence_NN of_IN patients_NNS with_IN diabetes_NN on_IN the_DT current_JJ register_NN ,_, there_EX will_MD be_VB about_RB 7500_CD patients_NNS on_IN the_DT system_NN if_IN 61_CD practices_NNS are_VBP recruited_VBN ._SENT Half_NN of_IN these_DT will_MD be_VB in_IN intervention_NN practices_NNS ._SENT On_IN current_JJ patterns_NNS of_IN usage_NN ,_, we_PP anticipate_VBP there_RB being_VBG the_DT need_NN for_IN 1.5_CD recalls_NNS per_IN annum_NN per_IN patient_NN on_IN the_DT register_NN ,_, resulting_VBG in_IN about_RB 6000_CD recalls_NNS per_IN year_NN for_IN the_DT intervention_NN group_NN ._SENT Assuming_VBG a_DT 40_CD week_NN working_VBG year_NN ,_, the_DT system_NN will_MD need_VB to_TO dispatch_VB ,_, receive_VB and_CC process_VB about_RB 150_CD forms_NNS per_IN group_NN per_IN week_NN ._SENT Identification_NN of_IN patients_NNS |_SYM Patients_NNS for_IN the_DT structured_JJ recall_NN and_CC management_NN system_NN are_VBP already_RB identified_VBN on_IN the_DT Hartlepool_NP and_CC North_NP Tees_NP database_NN ._SENT As_IN some_DT practices_NNS have_VBP children_NNS registered_VBN on_IN the_DT system_NN ,_, who_WP are_VBP under_IN the_DT care_NN of_IN an_DT exclusively_RB secondary_JJ care_NN adolescent_NN service_NN ,_, an_DT age_NN limit_NN of_IN 18_CD years_NNS or_CC over_RB will_MD be_VB set_VBN for_IN inclusion_NN ._SENT Practices_NNS will_MD be_VB asked_VBN to_TO check_VB lists_NNS of_IN their_PP$ patients_NNS on_IN the_DT database_NN regularly_RB throughout_IN the_DT study_NN ._SENT The_DT central_JJ database_NN will_MD remove_VB patients_NNS from_IN the_DT recall_NN system_NN who_WP are_VBP known_VBN to_TO have_VB died_VBN or_CC moved_VBN away_RB ._SENT Patient_JJ consent_NN |_SYM Patients_NNS have_VBP already_RB consented_VBN ,_, or_CC are_VBP being_VBG consented_VBN ,_, to_TO their_PP$ data_NNS being_VBG held_VBN within_IN the_DT current_JJ diabetes_NN register_NN ._SENT The_DT study_NN will_MD involve_VB no_RB extra_JJ '_'' routine_NN '_POS data_NNS being_VBG collected_VBN ,_, and_CC this_DT data_NNS will_MD be_VB anonymised_VBN before_IN being_VBG sent_VBN for_IN analysis_NN ;_: all_DT data_NNS held_VBN for_IN analysis_NN will_MD be_VB held_VBN in_IN accordance_NN with_IN the_DT Data_NP Protection_NP Act_NP ._SENT For_IN the_DT patient-based_JJ questionnaire_NN study_NN ,_, we_PP will_MD seek_VB additional_JJ patient_JJ consent_NN to_TO complete_VB one_CD survey_NN ._SENT The_DT three_CD relevant_JJ Local_NP Research_NP Ethics_NP Committees_NNS have_VBP approved_VBN the_DT trial_NN ._SENT Data_NNS collection_NN |_SYM The_DT main_JJ study_NN outcome_NN measures_NNS will_MD be_VB rates_NNS of_IN performance_NN of_IN process_NN of_IN care_NN and_CC the_DT patient_JJ based_VBN measures_NNS of_IN functional_JJ and_CC psychosocial_JJ wellbeing_NN ._SENT Data_NNS will_MD be_VB collected_VBN for_IN 15_CD months_NNS after_IN the_DT start_NN of_IN the_DT intervention_NN ._SENT Fifteen_CD months_NNS was_VBD chosen_VBN to_TO allow_VB for_IN patients_NNS who_WP are_VBP reviewed_VBN every_DT 12_CD months_NNS but_CC fail_VBP to_TO attend_VB on_IN initial_JJ invitation_NN ._SENT Process_NN of_IN care_NN variables_NNS |_SYM Process_NN of_IN care_NN variables_NNS will_MD be_VB collected_VBN via_IN the_DT computerised_VBN database_NN ._SENT The_DT exact_JJ data_NNS to_TO be_VB collected_VBN will_MD be_VB determined_VBN by_IN both_CC the_DT current_JJ content_NN of_IN the_DT database_NN and_CC the_DT guidelines_NNS but_CC will_MD include_VB such_JJ data_NNS items_NNS as_IN rates_NNS of_IN attendance_NN at_IN clinics_NNS and_CC annual_JJ reviews_NNS ,_, conduct_NN of_IN eye_NN and_CC feet_NNS examinations_NNS ,_, performance_NN of_IN investigations_NNS and_CC prescribing_VBG ._SENT We_PP will_MD also_RB collect_VB data_NNS on_IN clinical_JJ measures_NNS (_( e.g._FW HbA1c_NP ,_, and_CC blood_NN pressure_NN levels_NNS )_) ._SENT Outcome_NN of_IN care_NN measures_NNS |_SYM Outcome_JJ of_IN care_NN data_NNS will_MD be_VB collected_VBN ,_, by_IN postal_JJ questionnaire_NN ,_, 15_CD months_NNS after_IN commencement_NN of_IN the_DT study_NN ._SENT A_DT portfolio_NN of_IN validated_VBN and_CC responsive_JJ generic_JJ and_CC disease_NN specific_JJ instruments_NNS will_MD be_VB used_VBN to_TO measure_VB functional_JJ and_CC psychosocial_JJ variables_NNS that_WDT will_MD be_VB potentially_RB influenced_VBN by_IN the_DT intervention_NN ._SENT These_DT will_MD include_VB :_: i_NP )_) The_DT SF36_NP health_NN status_NN profile_NN which_WDT we_PP will_MD use_VB to_TO generate_VB Mental_NP (_( MCS_NP )_) and_CC Physical_NP Component_NP Summary_NP Scales_NP (_( PCS_NP )_) ._SENT ii_NP )_) The_DT Newcastle_NP Diabetes_NP Symptoms_NP Questionnaire_NP ._SENT iii_NP )_) The_DT Bradley_NP Treatment_NP Satisfaction_NP Questionnaire_NP ._SENT Patient_JJ costs_NNS questions_NNS will_MD be_VB developed_VBN by_IN the_DT study_NN health_NN economist_NN ._SENT We_PP have_VBP successfully_RB used_VBN such_JJ packages_NNS of_IN questionnaires_NNS within_IN trials_NNS before_RB and_CC have_VBP achieved_VBN response_NN rates_NNS in_IN excess_NN of_IN 70_CD %_NN in_IN similar_JJ surveys_NNS in_IN this_DT region_NN ._SENT ._SENT Sample_NN size_NN considerations_NNS |_SYM On_IN the_DT basis_NN of_IN previous_JJ work_NN we_PP have_VBP made_VBN the_DT following_VBG assumptions_NNS ._SENT The_DT mean_JJ number_NN of_IN patients_NNS per_IN practice_NN for_IN whom_WP we_PP will_MD be_VB able_JJ to_TO collect_VB process_NN data_NNS will_MD be_VB 30_CD and_CC the_DT ICC_NP (_( a_DT measure_NN of_IN the_DT lack_NN of_IN independence_NN of_IN responses_NNS from_IN patients_NNS from_IN the_DT same_JJ practice_NN )_) calculated_VBN from_IN our_PP$ local_JJ data_NNS is_VBZ 0.14_CD for_IN measures_NNS of_IN process_NN (_( whether_IN a_DT blood_NN pressure_NN measurement_NN and_CC whether_IN an_DT HbA1c_NP measurement_NN has_VBZ been_VBN recorded_VBN in_IN a_DT 12_CD month_NN period_NN )_) ._SENT Standard_JJ methods_NNS for_IN determining_VBG the_DT sample_NN size_NN requirements_NNS for_IN a_DT cluster_NN randomised_VBN trial_NN indicate_VBP that_IN we_PP need_VBP 60_CD practices_NNS to_TO detect_VB a_DT difference_NN of_IN 15_CD %_NN (_( 42.5_CD %_NN v_NN 57.5_CD %_NN )_) with_IN 80_CD %_NN power_NN assuming_VBG a_DT significance_NN level_NN of_IN 5_CD %_NN ._SENT Assessment_NN of_IN outcome_NN of_IN care_NN will_MD be_VB based_VBN on_IN health_NN status_NN scales_NNS such_JJ as_IN the_DT SF-36_NP ._SENT Previous_JJ work_NN has_VBZ shown_VBN that_IN this_DT type_NN of_IN intervention_NN is_VBZ likely_JJ to_TO produce_VB an_DT effect_NN size_NN of_IN approximately_RB 0.25_CD in_IN such_JJ measures_NNS and_CC that_IN the_DT ICCs_NNS for_IN such_JJ measures_NNS will_MD be_VB approximately_RB 0.07_CD ._SENT The_DT most_RBS efficient_JJ study_NN design_NN (_( that_WDT minimises_VBZ the_DT number_NN of_IN patients_NNS required_VBD )_) is_VBZ one_CD that_IN makes_NNS use_VBP of_IN all_PDT the_DT available_JJ practices_NNS ._SENT A_DT sample_NN of_IN 27_CD patients_NNS from_IN each_DT of_IN 61_CD practices_NNS will_MD give_VB us_PP 85_CD %_NN power_NN to_TO detect_VB an_DT effect_NN size_NN of_IN 0.25_CD assuming_VBG a_DT significance_NN level_NN of_IN 5_CD %_NN ._SENT With_IN a_DT predicted_VBN response_NN rate_NN of_IN approximately_RB 70_CD %_NN (_( based_VBN on_IN our_PP$ experience_NN in_IN the_DT COGENT_NP study_NN )_) after_IN two_CD reminders_NNS ,_, our_PP$ starting_VBG sample_NN size_NN will_MD need_VB to_TO be_VB 2379_CD patients_NNS (_( approximately_RB 39_CD patients_NNS per_IN practice_NN )_) ._SENT Principles_NNS of_IN data_NNS analysis_NN |_SYM Analysis_NN will_MD be_VB by_IN intention_NN to_TO treat_VB ._SENT Multilevel_JJ modelling_VBG (_( using_VBG the_DT MlwiN_NP package_NN )_) will_MD be_VB used_VBN to_TO take_VB into_IN account_NN the_DT clustering_VBG of_IN patients_NNS within_IN practices_NNS ._SENT Both_CC binary_JJ variables_NNS (_( when_WRB a_DT process_NN was_VBD undertaken_VBN or_CC not_RB )_) and_CC continuous_JJ variables_NNS (_( such_JJ as_IN the_DT physical_JJ health_NN component_NN of_IN the_DT SF-36_NP )_) can_MD be_VB analysed_VBN using_VBG these_DT techniques_NNS ._SENT For_IN both_DT types_NNS of_IN variable_NN ,_, variation_NN between_IN practices_NNS will_MD be_VB fitted_VBN as_IN a_DT random_JJ effect_NN and_CC the_DT difference_NN between_IN intervention_NN and_CC control_NN practices_NNS will_MD be_VB fitted_VBN as_IN a_DT fixed_VBN effect_NN ._SENT In_IN the_DT case_NN of_IN binary_JJ variables_NNS ,_, a_DT logit_NN link_NN function_NN will_MD be_VB used_VBN ._SENT Economic_JJ evaluation_NN |_SYM The_DT economic_JJ impact_NN of_IN implementing_VBG the_DT new_JJ structured_JJ recall_NN and_CC management_NN system_NN will_MD be_VB evaluated_VBN in_IN terms_NNS of_IN the_DT marginal_JJ costs_NNS of_IN adapting_VBG and_CC running_VBG the_DT system_NN ;_: the_DT costs_NNS of_IN developing_VBG and_CC disseminating_VBG the_DT guidelines_NNS ;_: the_DT educational_JJ activities_NNS for_IN intervention_NN practices_NNS ;_: the_DT implications_NNS for_IN the_DT use_NN of_IN health_NN care_NN services_NNS ;_: and_CC the_DT costs_NNS to_TO the_DT patients_NNS and_CC their_PP$ carers_NNS ._SENT The_DT benefits_NNS will_MD be_VB measured_VBN as_RB described_VBD earlier_RBR on_IN in_IN the_DT clinical_JJ study_NN ._SENT The_DT estimation_NN of_IN health_NN service_NN resource_NN use_NN will_MD relate_VB to_TO diabetes-specific_JJ clinical_JJ visits_NNS ,_, tests_NNS ,_, investigations_NNS ,_, and_CC procedures_NNS ._SENT This_DT data_NNS will_MD be_VB routinely_RB collected_VBN as_IN part_NN of_IN the_DT management_NN system_NN implementation_NN and_CC subsequent_JJ costing_VBG ,_, using_VBG health_NN service_NN pay_NN and_CC price_NN data_NNS ,_, will_MD be_VB undertaken_VBN using_VBG a_DT mixed_JJ approach_NN based_VBN on_IN micro-costing_NN and_CC gross-costing_NN methods_NNS ._SENT Use_NN of_IN drugs_NNS ,_, referrals_NNS to_TO secondary_JJ care_NN and_CC the_DT impact_NN of_IN the_DT intervention_NN on_IN the_DT change_NN of_IN use_NN of_IN patients_NNS '_'' and_CC their_PP$ carers_NNS '_POS time_NN will_MD also_RB be_VB monitored_VBN through_IN postal_JJ questionnaires_NNS at_IN the_DT end_NN of_IN the_DT follow-up_NN period_NN ._SENT A_DT sensitivity_NN analysis_NN will_MD be_VB undertaken_VBN to_TO test_VB the_DT robustness_NN of_IN the_DT results_NNS to_TO the_DT uncertainty_NN not_RB related_VBN to_TO sampling_VBG variations_NNS and_CC to_TO enhance_VB the_DT generalisability_NN of_IN the_DT results_NNS ._SENT We_PP are_VBP aware_JJ that_IN the_DT costs_NNS of_IN the_DT system_NN might_MD be_VB balanced_VBN only_RB in_IN the_DT longer_JJR term_NN against_IN the_DT cost_NN savings_NNS related_VBN to_TO averted_VBN complications_NNS ._SENT However_RB ,_, the_DT assessment_NN of_IN the_DT benefits_NNS in_IN terms_NNS of_IN final_JJ outcomes_NNS (_( e.g_NN lives_NNS saved_VBN ,_, or_CC QALYs_NP )_) and_CC long_JJ term_NN costs_NNS is_VBZ beyond_IN the_DT objective_NN of_IN the_DT present_JJ study_NN ._SENT None_NN declared_VBD publication_NN history_NN :_: The_DT pre-publication_NN history_NN for_IN this_DT paper_NN can_MD be_VB accessed_VBN here_RB :_: 